{"DataElement":{"publicId":"2950086","version":"1","preferredName":"Person Malignant Neoplasm Clinical Trial Eligibility Criteria Type","preferredDefinition":"The type of a person's cancer, diseases in which abnormal cells divide without control, as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"MALNEO_ELIG_TP","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"2950083","version":"1","preferredName":"Person Malignant Neoplasm Clinical Trial Eligibility Criteria","preferredDefinition":"information related to a person's cancer, diseases in which abnormal cells divide without control, as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:2950081v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2950081","version":"1","preferredName":"Malignant Neoplasm Clinical Trial Eligibility Criteria","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C9305:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74F8AF0F-EC47-C21E-E040-BB89AD430CC6","latestVersionIndicator":"Yes","beginDate":"2009-10-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-02","modifiedBy":"ONEDATA","dateModified":"2009-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74F8AF0F-EC58-C21E-E040-BB89AD430CC6","latestVersionIndicator":"Yes","beginDate":"2009-10-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-02","modifiedBy":"TAYLORT","dateModified":"2018-02-08","changeDescription":"2/8/18 tt received CTEP approval from BC to transfer ownership to ECOG-ACRIN context.  Added Reg Status and CSI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2950084","version":"1","preferredName":"Person Malignant Neoplasm Clinical Trial Eligibility Criteria Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"2950084","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Acute Myeloid Leukemia, NOS","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2581275","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"2581275","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A88-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"74F8AF0F-EC9D-C21E-E040-BB89AD430CC6","beginDate":"2009-10-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-02","modifiedBy":"ONEDATA","dateModified":"2009-10-02","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome, NOS","valueDescription":"Myelodysplastic Syndrome","ValueMeaning":{"publicId":"2570433","version":"1","preferredName":"Myelodysplastic Syndrome","longName":"2570433","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E02E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"74F8AF0F-EC88-C21E-E040-BB89AD430CC6","beginDate":"2009-10-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-02","modifiedBy":"ONEDATA","dateModified":"2009-10-02","deletedIndicator":"No"},{"value":"Chronic Myelomonocytic Leukemia","valueDescription":"Chronic Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2771865","version":"1","preferredName":"Chronic Myelomonocytic Leukemia","longName":"2771865","preferredDefinition":"A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myelomonocytic Leukemia","conceptCode":"C3178","definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54342348-5E2F-4602-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SOKKERL","dateModified":"2022-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"74F8AF0F-ECA7-C21E-E040-BB89AD430CC6","beginDate":"2009-10-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-02","modifiedBy":"ONEDATA","dateModified":"2009-10-02","deletedIndicator":"No"},{"value":"Myeloma, NOS","valueDescription":"Myeloma","ValueMeaning":{"publicId":"2838667","version":"1","preferredName":"Myeloma","longName":"2838667","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-9631-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75819AE4-A77A-9D30-E040-BB89AD430B21","beginDate":"2009-10-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-09","modifiedBy":"ONEDATA","dateModified":"2009-10-09","deletedIndicator":"No"},{"value":"Monoclonal gammopathy of undetermined significance (MGUS)","valueDescription":"Monoclonal Gammopathy of Undetermined Significance","ValueMeaning":{"publicId":"2838621","version":"1","preferredName":"Monoclonal Gammopathy of Undetermined Significance","longName":"2838621","preferredDefinition":"A plasma cell disorder in which an abnormal amount of a single immunoglobulin is present in the serum. Up to 25% of cases of monoclonal gammopathy of undetermined significance (MGUS) progress to a B-cell malignancy or myeloma. MGUS may occur in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Gammopathy of Undetermined Significance","conceptCode":"C3996","definition":"A condition in which an abnormal amount of a single immunoglobulin is present in the serum. This category includes IgM monoclonal gammopathy of undetermined significance and non-IgM monoclonal gammopathy of undetermined significance. Up to 25% of cases of monoclonal gammopathy of undetermined significance  progress to a B-cell malignancy or myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B0A2-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75819AE4-A78F-9D30-E040-BB89AD430B21","beginDate":"2009-10-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-09","modifiedBy":"ONEDATA","dateModified":"2009-10-09","deletedIndicator":"No"},{"value":"Solitary Plasmacytoma","valueDescription":"Solitary Plasmacytoma","ValueMeaning":{"publicId":"2951236","version":"1","preferredName":"Solitary Plasmacytoma","longName":"2951236","preferredDefinition":"A single focus of clonal (malignant) plasma cells either in the bone or in another anatomic site without peripheral blood involvement. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solitary Plasmacytoma","conceptCode":"C6932","definition":"A localized malignant neoplasm that arises in the bony skeleton or soft tissue. It is composed of clonal (malignant) plasma cells forming a tumor mass.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75819AE4-A79A-9D30-E040-BB89AD430B21","latestVersionIndicator":"Yes","beginDate":"2009-10-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75819AE4-A7B3-9D30-E040-BB89AD430B21","beginDate":"2009-10-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-09","modifiedBy":"ONEDATA","dateModified":"2009-10-09","deletedIndicator":"No"},{"value":"Lung Adenocarcinoma with bronchioloalveolar features","valueDescription":"Bronchioloalveolar Carcinoma Lung Adenocarcinoma","ValueMeaning":{"publicId":"3106710","version":"1","preferredName":"Bronchioloalveolar Carcinoma Lung Adenocarcinoma","longName":"3106710","preferredDefinition":"A well or moderately differentiated morphologic variant of lung adenocarcinoma characterized by tumor growth along the alveolar structures without stromal, vascular, or pleural invasion.: A carcinoma characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimally Invasive Lung Adenocarcinoma","conceptCode":"C2923","definition":"A solitary adenocarcinoma arising from the lung and measuring 3 cm or less in size. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lung Adenocarcinoma","conceptCode":"C3512","definition":"A carcinoma that arises from the lung and is characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883834AB-0CDD-C6A6-E040-BB89AD431A8D","latestVersionIndicator":"Yes","beginDate":"2010-06-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"883834AB-0CF6-C6A6-E040-BB89AD431A8D","beginDate":"2010-06-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-04","modifiedBy":"ONEDATA","dateModified":"2010-06-04","deletedIndicator":"No"},{"value":"Non-Small Cell Lung Cancer, NOS","valueDescription":"Not Otherwise Specified NSCLC","ValueMeaning":{"publicId":"3113369","version":"1","preferredName":"Not Otherwise Specified NSCLC","longName":"3113369","preferredDefinition":"Not characterized in any other way.: A group of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.  Non-small cell lung carcinomas have a poor response to conventional chemotherapy.  --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lung Non-Small Cell Carcinoma","conceptCode":"C2926","definition":"A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"899F4FC5-DA60-3A4B-E040-BB89AD436E3E","latestVersionIndicator":"Yes","beginDate":"2010-06-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-22","modifiedBy":"ONEDATA","dateModified":"2010-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"899F4FC5-DA79-3A4B-E040-BB89AD436E3E","beginDate":"2010-06-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-22","modifiedBy":"ONEDATA","dateModified":"2010-06-22","deletedIndicator":"No"},{"value":"Bronchioloalveolar carcinoma","valueDescription":"Bronchioalveolar Carcinoma","ValueMeaning":{"publicId":"3106712","version":"1","preferredName":"Bronchioalveolar Carcinoma","longName":"3106712","preferredDefinition":"A solitary adenocarcinoma arising from the lung measuring 3 cm or less. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimally Invasive Lung Adenocarcinoma","conceptCode":"C2923","definition":"A solitary adenocarcinoma arising from the lung and measuring 3 cm or less in size. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883834AB-0D26-C6A6-E040-BB89AD431A8D","latestVersionIndicator":"Yes","beginDate":"2010-06-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-04","modifiedBy":"COOPERM","dateModified":"2019-04-10","changeDescription":"Updated definition to match current NCIt. 4.10.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"883834AB-0D3F-C6A6-E040-BB89AD431A8D","beginDate":"2010-06-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-04","modifiedBy":"ONEDATA","dateModified":"2010-06-04","deletedIndicator":"No"},{"value":"Lung Adenocarcinoma","valueDescription":"Lung Adenocarcinoma","ValueMeaning":{"publicId":"3106713","version":"1","preferredName":"Lung Adenocarcinoma","longName":"3106713","preferredDefinition":"A carcinoma characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Adenocarcinoma","conceptCode":"C3512","definition":"A carcinoma that arises from the lung and is characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883834AB-0D4B-C6A6-E040-BB89AD431A8D","latestVersionIndicator":"Yes","beginDate":"2010-06-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"883834AB-0D64-C6A6-E040-BB89AD431A8D","beginDate":"2010-06-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-04","modifiedBy":"ONEDATA","dateModified":"2010-06-04","deletedIndicator":"No"},{"value":"Non-small cell carcinoma, NOS","valueDescription":"Not Otherwise Specified Non-Small Cell Carcinoma","ValueMeaning":{"publicId":"3106711","version":"1","preferredName":"Not Otherwise Specified Non-Small Cell Carcinoma","longName":"3106711","preferredDefinition":"Not characterized in any other way.: A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Non-Small Cell Carcinoma","conceptCode":"C65151","definition":"A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883834AB-0D03-C6A6-E040-BB89AD431A8D","latestVersionIndicator":"Yes","beginDate":"2010-06-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"893F766C-7333-C216-E040-BB89AD432929","beginDate":"2010-06-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"ONEDATA","dateModified":"2010-06-17","deletedIndicator":"No"},{"value":"Adenocarcinoma of the gastroesophageal junction","valueDescription":"Adenocarcinoma of the gastroesophageal junction","ValueMeaning":{"publicId":"3131360","version":"1","preferredName":"Adenocarcinoma of the gastroesophageal junction","longName":"3131360","preferredDefinition":"An adenocarcinoma that arises from and straddles the junction of the stomach and esophagus.  The category of adenocarcinomas of the gastroesophageal junction also includes the majority of adenocarcinomas previously called gastric cardia adenocarcinomas.  Squamous cell carcinomas that affect or cross the junction of the stomach and esophagus are classified as carcinomas of the distal esophagus.  Adenocarcinoma of the gastroesophageal junction occurs more often in Caucasian middle aged and elderly males.  Clinical signs and symptoms include dysphagia, abdominal pain, and weight loss.  The prognosis depends on the completeness of the surgical resection, the number of lymph nodes involved by cancer, and the presence or absence of postoperative complications.  The presence of TP53 mutations indicates worse prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastroesophageal Junction Adenocarcinoma","conceptCode":"C9296","definition":"An adenocarcinoma that arises from and straddles the junction of the stomach and esophagus. The category of adenocarcinomas of the gastroesophageal junction also includes the majority of adenocarcinomas previously called gastric cardia adenocarcinomas. Squamous cell carcinomas that affect or cross the junction of the stomach and esophagus are classified as carcinomas of the distal esophagus. Adenocarcinoma of the gastroesophageal junction occurs more often in Caucasian middle aged and elderly males. Clinical signs and symptoms include dysphagia, abdominal pain, and weight loss. The prognosis depends on the completeness of the surgical resection, the number of lymph nodes involved by cancer, and the presence or absence of postoperative complications. The presence of TP53 mutations indicates worse prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E826809-6A0A-B693-E040-BB89AD431378","latestVersionIndicator":"Yes","beginDate":"2010-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-23","modifiedBy":"ZHANGW","dateModified":"2021-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E826809-6A23-B693-E040-BB89AD431378","beginDate":"2010-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-23","modifiedBy":"ONEDATA","dateModified":"2010-08-23","deletedIndicator":"No"},{"value":"Squamous cell carcinoma of the esophagus","valueDescription":"Squamous cell carcinoma of the esophagus","ValueMeaning":{"publicId":"3131361","version":"1","preferredName":"Squamous cell carcinoma of the esophagus","longName":"3131361","preferredDefinition":"cancer that begins in flat cells lining the esophagus","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E826809-6A2D-B693-E040-BB89AD431378","latestVersionIndicator":"Yes","beginDate":"2010-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E826809-6A46-B693-E040-BB89AD431378","beginDate":"2010-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-23","modifiedBy":"ONEDATA","dateModified":"2010-08-23","deletedIndicator":"No"},{"value":"Esophageal cancer, NOS","valueDescription":"Esophageal cancer, NOS","ValueMeaning":{"publicId":"3131362","version":"1","preferredName":"Esophageal cancer, NOS","longName":"3131362","preferredDefinition":"A malignancy that develops in tissues of the hollow, muscular canal (esophagus) along which food and liquid travel from the throat to the stomach.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E826809-6A50-B693-E040-BB89AD431378","latestVersionIndicator":"Yes","beginDate":"2010-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E826809-6A69-B693-E040-BB89AD431378","beginDate":"2010-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-23","modifiedBy":"ONEDATA","dateModified":"2010-08-23","deletedIndicator":"No"},{"value":"Adenocarcinoma of the esophagus","valueDescription":"Adenocarcinoma of the esophagus","ValueMeaning":{"publicId":"3131363","version":"1","preferredName":"Adenocarcinoma of the esophagus","longName":"3131363","preferredDefinition":"A malignant tumor in which cancer cells form in the glandular lining of the lower esophagus","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E826809-6A73-B693-E040-BB89AD431378","latestVersionIndicator":"Yes","beginDate":"2010-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E826809-6A8C-B693-E040-BB89AD431378","beginDate":"2010-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-23","modifiedBy":"ONEDATA","dateModified":"2010-08-23","deletedIndicator":"No"},{"value":"Oligodendroglioma, NOS","valueDescription":"Oligodendroglioma","ValueMeaning":{"publicId":"2838655","version":"1","preferredName":"Oligodendroglioma","longName":"2838655","preferredDefinition":"A well-differentiated (WHO grade II), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligodendroglioma","conceptCode":"C3288","definition":"A well-differentiated (WHO grade 2), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A770F5-59CD-03F5-E040-BB89AD435AD2","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B38490CA-162E-A4CE-E040-BB89AD430D6C","beginDate":"2011-12-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"CNS primary tumor, NOS","valueDescription":"CNS primary tumor, NOS","ValueMeaning":{"publicId":"3325249","version":"1","preferredName":"CNS primary tumor, NOS","longName":"3325249","preferredDefinition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.::1: A tumor at the original site of origin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System","conceptCode":"C12438","definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Primary Neoplasm","conceptCode":"C8509","definition":"A tumor at the original site of origin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B38490CA-1639-A4CE-E040-BB89AD430D6C","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B38490CA-1652-A4CE-E040-BB89AD430D6C","beginDate":"2011-12-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Low-grade astrocytoma, NOS","valueDescription":"Low-grade astrocytoma, NOS","ValueMeaning":{"publicId":"3325250","version":"1","preferredName":"Low-grade astrocytoma, NOS","longName":"3325250","preferredDefinition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.::1: A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low Grade","conceptCode":"C14161","definition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B38490CA-165C-A4CE-E040-BB89AD430D6C","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B38490CA-1675-A4CE-E040-BB89AD430D6C","beginDate":"2011-12-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Neuroendocrine cancer, NOS","valueDescription":"Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"2559503","version":"1","preferredName":"Neuroendocrine Carcinoma","longName":"2559503","preferredDefinition":"A malignant neuroendocrine tumor composed of cells containing secretory granules that stain positive for NSE and chromogranin.  Tumor cells are often round and form clusters or trabecular sheets.  Representative examples are carcinoid tumor, small cell carcinoma, and Merkel cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroendocrine Carcinoma","conceptCode":"C3773","definition":"A usually aggressive carcinoma composed of malignant cells exhibiting neuroendocrine differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B57C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D6A1A0E7-D3A7-09EA-E040-BB89AD4351B5","beginDate":"2013-02-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-02-26","modifiedBy":"ONEDATA","dateModified":"2013-02-26","deletedIndicator":"No"},{"value":"Islet cell tumors of the pancreas","valueDescription":"Pancreatic Neuroendocrine Tumor","ValueMeaning":{"publicId":"3250495","version":"1","preferredName":"Pancreatic Neuroendocrine Tumor","longName":"3250495","preferredDefinition":"A low or intermediate grade well differentiated tumor with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Neuroendocrine Tumor","conceptCode":"C27720","definition":"A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6F215E6-C657-B293-E040-BB89AD432EF3","latestVersionIndicator":"Yes","beginDate":"2011-06-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D6B58A11-CDA2-2445-E040-BB89AD436309","beginDate":"2013-02-27","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-02-27","modifiedBy":"ONEDATA","dateModified":"2013-02-27","deletedIndicator":"No"},{"value":"Head and neck squamous cell carcinoma, NOS","valueDescription":"Head and Neck Squamous Cell Carcinoma","ValueMeaning":{"publicId":"3088073","version":"1","preferredName":"Head and Neck Squamous Cell Carcinoma","longName":"3088073","preferredDefinition":"A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Head and Neck Squamous Cell Carcinoma","conceptCode":"C34447","definition":"A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E18C0F-E39C-9226-E040-BB89AD430EF0","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-18","modifiedBy":"ZHANGW","dateModified":"2021-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E010110A-EA28-64DE-E040-BB89AD431324","beginDate":"2013-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-06-26","modifiedBy":"ONEDATA","dateModified":"2013-06-26","deletedIndicator":"No"},{"value":"Pharyngeal Squamous Cell Carcinoma","valueDescription":"Pharyngeal Squamous Cell Carcinoma","ValueMeaning":{"publicId":"3794702","version":"1","preferredName":"Pharyngeal Squamous Cell Carcinoma","longName":"3794702","preferredDefinition":"A squamous cell carcinoma that arises from the pharynx.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharyngeal Squamous Cell Carcinoma","conceptCode":"C102872","definition":"A squamous cell carcinoma that arises from the pharynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E010110A-EA36-64DE-E040-BB89AD431324","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E010110A-EA4F-64DE-E040-BB89AD431324","beginDate":"2013-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-06-26","modifiedBy":"ONEDATA","dateModified":"2013-06-26","deletedIndicator":"No"},{"value":"Lip and Oral Cavity Squamous Cell Carcinoma","valueDescription":"Lip and Oral Cavity Squamous Cell Carcinoma","ValueMeaning":{"publicId":"3794704","version":"1","preferredName":"Lip and Oral Cavity Squamous Cell Carcinoma","longName":"3794704","preferredDefinition":"A squamous cell carcinoma arising from the lip or the oral cavity.  The oral cavity squamous cell carcinoma usually arises from the buccal mucosa, tongue, or gums.  It occurs predominantly in adults who use tobacco and alcohol and has a tendency to metastasize early to lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lip and Oral Cavity Squamous Cell Carcinoma","conceptCode":"C42690","definition":"A squamous cell carcinoma arising from the lip or the oral cavity.  The oral cavity squamous cell carcinoma usually arises from the buccal mucosa, tongue, or gums.  It occurs predominantly in adults who use tobacco and alcohol and has a tendency to metastasize early to lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E010110A-EA5C-64DE-E040-BB89AD431324","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E010110A-EA75-64DE-E040-BB89AD431324","beginDate":"2013-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-06-26","modifiedBy":"ONEDATA","dateModified":"2013-06-26","deletedIndicator":"No"},{"value":"Laryngeal Squamous Cell Carcinoma","valueDescription":"Laryngeal Squamous Cell Carcinoma","ValueMeaning":{"publicId":"3794706","version":"1","preferredName":"Laryngeal Squamous Cell Carcinoma","longName":"3794706","preferredDefinition":"A squamous cell carcinoma arising from the larynx.  It is the most common type of laryngeal carcinoma.  The site of origin within the larynx influences the symptoms, histologic characteristics, and clinical behavior of squamous cell carcinoma.  The laryngeal squamous cell carcinomas can be glottic, supraglottic, and transglottic.  Glottic carcinoma is the most frequent form of laryngeal carcinoma in the United States.  Microscopically, squamous cell carcinomas of the larynx are similar in their appearance to squamous cell carcinomas arising elsewhere (adapted from Sternberg's Diagnostic Surgical Pathology, 3rd ed., 1999).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laryngeal Squamous Cell Carcinoma","conceptCode":"C4044","definition":"A squamous cell carcinoma that arises from the larynx.  It is the most common histologic type of laryngeal carcinoma.  It can arise from the glottis, supraglottic area, or it can be transglottic.  Glottic squamous cell carcinoma is the most frequent laryngeal carcinoma in the United States.  The symptoms, clinical behavior and the prognosis depend on the site of origin within the larynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E010110A-EA82-64DE-E040-BB89AD431324","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E010110A-EA9B-64DE-E040-BB89AD431324","beginDate":"2013-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-06-26","modifiedBy":"ONEDATA","dateModified":"2013-06-26","deletedIndicator":"No"},{"value":"Nodal marginal zone B-cell lymphoma","valueDescription":"Nodal Marginal Zone B-Cell Lymphoma","ValueMeaning":{"publicId":"2838642","version":"1","preferredName":"Nodal Marginal Zone B-Cell Lymphoma","longName":"2838642","preferredDefinition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodal Marginal Zone Lymphoma","conceptCode":"C8863","definition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-5AB3-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D7FC18AD-46C6-6F75-E040-BB89AD4327FA","beginDate":"2013-03-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-03-15","modifiedBy":"ONEDATA","dateModified":"2013-03-15","deletedIndicator":"No"},{"value":"Small lymphocytic lymphoma, NOS","valueDescription":"Small Lymphocytic Lymphoma","ValueMeaning":{"publicId":"3251329","version":"1","preferredName":"Small Lymphocytic Lymphoma","longName":"3251329","preferredDefinition":"An indolent non-Hodgkin's lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process involves predominantly the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Lymphocytic Lymphoma","conceptCode":"C7540","definition":"A non-Hodgkin lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process predominantly involves the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9BA2-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"COOPERM","dateModified":"2011-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D7FC18AD-46DB-6F75-E040-BB89AD4327FA","beginDate":"2013-03-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-03-15","modifiedBy":"ONEDATA","dateModified":"2013-03-15","deletedIndicator":"No"},{"value":"Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)","valueDescription":"Lymphoplasmacytic Lymphoma","ValueMeaning":{"publicId":"2629954","version":"1","preferredName":"Lymphoplasmacytic Lymphoma","longName":"2629954","preferredDefinition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoplasmacytic Lymphoma","conceptCode":"C3212","definition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E665ACD-9834-52CE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-18","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-04-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Added NCIt concept.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D7FC18AD-46F0-6F75-E040-BB89AD4327FA","beginDate":"2013-03-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-03-15","modifiedBy":"ONEDATA","dateModified":"2013-03-15","deletedIndicator":"No"},{"value":"Mantle cell lymphoma","valueDescription":"Mantle Cell Lymphoma","ValueMeaning":{"publicId":"2838603","version":"1","preferredName":"Mantle Cell Lymphoma","longName":"2838603","preferredDefinition":"An aggressive, usually diffuse non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes).  Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement.  The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma.  The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mantle Cell Lymphoma","conceptCode":"C4337","definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE62-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D7FC18AD-46FB-6F75-E040-BB89AD4327FA","beginDate":"2013-03-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-03-15","modifiedBy":"ONEDATA","dateModified":"2013-03-15","deletedIndicator":"No"},{"value":"Follicular lymphoma","valueDescription":"Follicular Lymphoma","ValueMeaning":{"publicId":"3088584","version":"1","preferredName":"Follicular Lymphoma","longName":"3088584","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D19B-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D7FC18AD-4710-6F75-E040-BB89AD4327FA","beginDate":"2013-03-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-03-15","modifiedBy":"ONEDATA","dateModified":"2013-03-15","deletedIndicator":"No"},{"value":"Adenocarcinoma of the pancreas","valueDescription":"Adenocarcinoma of the pancreas","ValueMeaning":{"publicId":"4363409","version":"1","preferredName":"Adenocarcinoma of the pancreas","longName":"4363409","preferredDefinition":"An adenocarcinoma which arises from the exocrine pancreas.  Ductal adenocarcinoma and its variants are the most common types of pancreatic adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Adenocarcinoma","conceptCode":"C8294","definition":"An adenocarcinoma which arises from the exocrine pancreas.  Ductal adenocarcinoma and its variants are the most common types of pancreatic adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC824337-6B49-3D12-E040-BB89AD435880","latestVersionIndicator":"Yes","beginDate":"2014-06-23","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-06-23","modifiedBy":"ZHANGW","dateModified":"2021-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC824337-6B62-3D12-E040-BB89AD435880","beginDate":"2014-06-23","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-06-23","modifiedBy":"ONEDATA","dateModified":"2014-06-23","deletedIndicator":"No"},{"value":"Pancreatic cancer (excluding Islets), NOS","valueDescription":"Pancreatic cancer (excluding Islets), NOS","ValueMeaning":{"publicId":"4363410","version":"1","preferredName":"Pancreatic cancer (excluding Islets), NOS","longName":"4363410","preferredDefinition":"A carcinoma arising from the exocrine pancreas. The overwhelming majority of pancreatic carcinomas are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Carcinoma","conceptCode":"C3850","definition":"A carcinoma arising from the exocrine pancreas. The overwhelming majority of pancreatic carcinomas are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC824337-6B6C-3D12-E040-BB89AD435880","latestVersionIndicator":"Yes","beginDate":"2014-06-23","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-06-23","modifiedBy":"ZHANGW","dateModified":"2021-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC824337-6B85-3D12-E040-BB89AD435880","beginDate":"2014-06-23","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-06-23","modifiedBy":"ONEDATA","dateModified":"2014-06-23","deletedIndicator":"No"},{"value":"Inflammatory breast carcinoma","valueDescription":"Inflammatory Breast Carcinoma","ValueMeaning":{"publicId":"2593123","version":"1","preferredName":"Inflammatory Breast Carcinoma","longName":"2593123","preferredDefinition":"A type of breast cancer in which the breast looks red and swollen and feels warm. The skin of the breast may also show the pitted appearance called peau d'orange (like the skin of an orange). The redness and warmth occur because the cancer cells block the lymph vessels in the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Inflammatory Carcinoma","conceptCode":"C4001","definition":"An advanced, invasive breast adenocarcinoma characterized by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D4DB6-4D39-242A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4079EE9-DEC8-5342-E040-BB89AD436502","beginDate":"2014-03-07","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-03-07","modifiedBy":"ONEDATA","dateModified":"2014-03-07","deletedIndicator":"No"},{"value":"Invasive breast carcinoma","valueDescription":"Invasive breast cancer","ValueMeaning":{"publicId":"2576315","version":"1","preferredName":"Invasive breast cancer","longName":"2576315","preferredDefinition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Breast Carcinoma","conceptCode":"C9245","definition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F728-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-09-21","modifiedBy":"ZHANGW","dateModified":"2021-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4079EE9-DEDC-5342-E040-BB89AD436502","beginDate":"2014-03-07","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-03-07","modifiedBy":"ONEDATA","dateModified":"2014-03-07","deletedIndicator":"No"},{"value":"Breast Cancer, NOS","valueDescription":"Breast cancer, NOS","ValueMeaning":{"publicId":"3442388","version":"1","preferredName":"Breast cancer, NOS","longName":"3442388","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE840591-091B-69F7-E040-BB89AD4368BA","latestVersionIndicator":"Yes","beginDate":"2012-04-25","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-04-25","modifiedBy":"ZHANGW","dateModified":"2021-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEDBA90D-B547-B5B0-E040-BB89AD433625","beginDate":"2014-07-23","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-23","modifiedBy":"ONEDATA","dateModified":"2014-07-23","deletedIndicator":"No"},{"value":"Adenocarcinoma of the esophagus/stomach","valueDescription":"Adenocarcinoma of the esophagus/stomach","ValueMeaning":{"publicId":"4666891","version":"1","preferredName":"Adenocarcinoma of the esophagus/stomach","longName":"4666891","preferredDefinition":"Adenocarcinoma of the esophagus/stomach","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CA0E650-03DE-6E54-E050-BB89AD431DF5","latestVersionIndicator":"Yes","beginDate":"2015-01-14","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CA0E650-03F7-6E54-E050-BB89AD431DF5","beginDate":"2015-01-14","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-14","modifiedBy":"ONEDATA","dateModified":"2015-01-14","deletedIndicator":"No"},{"value":"Adenocarcinoma of the stomach","valueDescription":"Gastric Adenocarcinoma","ValueMeaning":{"publicId":"3206052","version":"1","preferredName":"Gastric Adenocarcinoma","longName":"3206052","preferredDefinition":"An adenocarcinoma arising from the stomach glandular epithelium. Gastric adenocarcinoma is primarily a disease of older individuals, most commonly develops after a long period of atrophic gastritis and is strongly associated with Helicobacter pylori infection. The lack of early symptoms often delays the diagnosis of gastric cancer. The majority of patients present with advanced tumors which have poor rates of curability. Microscopically, two important histologic types of gastric adenocarcinoma are recognized: the intestinal and diffuse type. The overall prognosis of gastric adenocarcinomas is poor, even in patients who receive a \"curative\" resection (adapted from Sternberg's Surgical Pathology, 3rd ed., 1999).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Adenocarcinoma","conceptCode":"C4004","definition":"An adenocarcinoma arising from the stomach glandular epithelium. Gastric adenocarcinoma is primarily a disease of older individuals.  It most commonly develops after a long period of atrophic gastritis and is strongly associated with Helicobacter pylori infection. The lack of early symptoms often delays the diagnosis of gastric cancer. The majority of patients present with advanced tumors which have poor rates of curability. Microscopically, two important histologic types of gastric adenocarcinoma are recognized: the intestinal and diffuse type. The overall prognosis of gastric adenocarcinomas is poor, even in patients who receive a \"curative\" resection (adapted from Sternberg's Surgical Pathology, 3rd ed., 1999).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F03F2AF-4F8F-0E9A-E040-BB89AD436762","latestVersionIndicator":"Yes","beginDate":"2011-03-21","endDate":null,"createdBy":"BLABOLIJ","dateCreated":"2011-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F70C43F-8228-1C74-E050-BB89AD434C96","beginDate":"2015-02-19","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-02-19","modifiedBy":"ONEDATA","dateModified":"2015-02-19","deletedIndicator":"No"},{"value":"Squamous cell lung carcinoma","valueDescription":"Squamous Cell Lung Carcinoma","ValueMeaning":{"publicId":"2956083","version":"1","preferredName":"Squamous Cell Lung Carcinoma","longName":"2956083","preferredDefinition":"A carcinoma arising from malignant squamous bronchial epithelial cells and characterized by the presence of keratinization and/or intercellular bridges.  Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Squamous Cell Carcinoma","conceptCode":"C3493","definition":"A carcinoma arising from squamous bronchial epithelial cells. It may be keratinizing or non-keratinizing. Keratinizing squamous cell carcinoma is characterized by the presence of keratinization, pearl formation, and/or intercellular bridges. Non-keratinizing squamous cell carcinoma is characterized by the absence of keratinization, pearl formation, and intercellular bridges. Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76EBECE2-B835-A0E2-E040-BB89AD435984","latestVersionIndicator":"Yes","beginDate":"2009-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"23D0CEAA-76EC-0EC2-E050-BB89AD436228","beginDate":"2015-11-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-11-05","modifiedBy":"ONEDATA","dateModified":"2015-11-05","deletedIndicator":"No"},{"value":"Primary peritoneal carcinoma","valueDescription":"Primary Peritoneal Carcinoma","ValueMeaning":{"publicId":"4722587","version":"1","preferredName":"Primary Peritoneal Carcinoma","longName":"4722587","preferredDefinition":"A rare carcinoma that arises from the peritoneum and resembles the malignant surface epithelial-stromal tumors that arise from the ovary.  Serous adenocarcinoma is the most common histologic variant. It affects women almost exclusively.  The diagnosis of primary peritoneal carcinoma can be made only if both ovaries are not involved by tumor, or, if the ovaries are involved, the tumor is confined to the ovarian surface without invasion of the ovarian stroma and the peritoneal involvement is greater than the ovarian surface involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Peritoneal Carcinoma","conceptCode":"C40022","definition":"A rare carcinoma that arises from the peritoneum and resembles the malignant surface epithelial-stromal tumors that arise from the ovary.  Serous adenocarcinoma is the most common histologic variant. It affects women almost exclusively.  The diagnosis of primary peritoneal carcinoma can be made only if both ovaries are not involved by tumor, or, if the ovaries are involved, the tumor is confined to the ovarian surface without invasion of the ovarian stroma and the peritoneal involvement is greater than the ovarian surface involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B9DC-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64B4DA7C-9902-6628-E053-F662850A3E01","beginDate":"2018-02-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-08","modifiedBy":"ONEDATA","dateModified":"2018-02-08","deletedIndicator":"No"},{"value":"Ovarian epithelial cancer","valueDescription":"Ovarian Epithelium Malignant Neoplasm","ValueMeaning":{"publicId":"6063737","version":"1","preferredName":"Ovarian Epithelium Malignant Neoplasm","longName":"6063737","preferredDefinition":"Having to do with the ovaries, the female reproductive glands in which the ova (eggs) are formed. The ovaries are located in the pelvis, one on each side of the uterus.: One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian","conceptCode":"C28047","definition":"Having to do with the ovaries, the female reproductive glands in which the ova (eggs) are formed. The ovaries are located in the pelvis, one on each side of the uterus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Epithelium","conceptCode":"C12710","definition":"The avascular cellular layers that cover body surfaces and cavities and may form glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"64B4DA7C-9911-6628-E053-F662850A3E01","latestVersionIndicator":"Yes","beginDate":"2018-02-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-08","modifiedBy":"ONEDATA","dateModified":"2018-02-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64B4DA7C-992A-6628-E053-F662850A3E01","beginDate":"2018-02-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-08","modifiedBy":"ONEDATA","dateModified":"2018-02-08","deletedIndicator":"No"},{"value":"Fallopian tube carcinoma","valueDescription":"Fallopian Tube Carcinoma","ValueMeaning":{"publicId":"3210700","version":"1","preferredName":"Fallopian Tube Carcinoma","longName":"3210700","preferredDefinition":"A carcinoma arising from the fallopian tube which is attached to the uterine corpus (uterine body). Most patients are postmenopausal, and postmenopausal bleeding is the most frequently seen symptom. Morphologically, the majority of fallopian tube carcinomas are serous or endometrioid adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fallopian Tube Carcinoma","conceptCode":"C3867","definition":"A carcinoma arising from the fallopian tube. Most patients are postmenopausal, and postmenopausal bleeding is the most frequently seen symptom. Morphologically, the majority of fallopian tube carcinomas are serous or endometrioid adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9080-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64B4DA7C-9953-6628-E053-F662850A3E01","beginDate":"2018-02-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-08","modifiedBy":"ONEDATA","dateModified":"2018-02-08","deletedIndicator":"No"},{"value":"Precursor T-lymphoblastic leukemia (T-cell ALL)","valueDescription":"T Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4263973","version":"1","preferredName":"T Acute Lymphoblastic Leukemia","longName":"4263973","preferredDefinition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Acute Lymphoblastic Leukemia","conceptCode":"C3183","definition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1133-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A3C936-00C0-0B99-E053-F662850AD4E5","beginDate":"2018-03-30","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Precursor B-lymphoblastic leukemia (B-precursor ALL)","valueDescription":"B Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4263974","version":"1","preferredName":"B Acute Lymphoblastic Leukemia","longName":"4263974","preferredDefinition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia","conceptCode":"C8644","definition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1156-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A3C936-00D4-0B99-E053-F662850AD4E5","beginDate":"2018-03-30","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Acute lymphoblastic leukemia, NOS","valueDescription":"Acute Lymphoblastic Leukemia Not Otherwise Specified","ValueMeaning":{"publicId":"3322386","version":"1","preferredName":"Acute Lymphoblastic Leukemia Not Otherwise Specified","longName":"3322386","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BBDB-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E0E69E-0F2C-650C-E053-F662850A341F","beginDate":"2018-04-02","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Acute lymphoblastic leukemia","valueDescription":"Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"3322383","version":"1","preferredName":"Acute Lymphoblastic Leukemia","longName":"3322383","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB5D-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E0E69E-0F40-650C-E053-F662850A341F","beginDate":"2018-03-30","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Ovarian cancer NOS","valueDescription":"Ovarian Carcinoma Not Otherwise Specified ","ValueMeaning":{"publicId":"5581338","version":"1","preferredName":"Ovarian Carcinoma Not Otherwise Specified ","longName":"5581338","preferredDefinition":"Not characterized in any other way.: A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms. --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ovarian Carcinoma","conceptCode":"C4908","definition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B816-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"TAYLORT","dateModified":"2018-02-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D76D4E3-005C-6A41-E053-F662850A1845","beginDate":"2018-02-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-20","modifiedBy":"ONEDATA","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Lung Cancer, NOS","valueDescription":"Lung Carcinoma Not Otherwise Specified","ValueMeaning":{"publicId":"3323202","version":"1","preferredName":"Lung Carcinoma Not Otherwise Specified","longName":"3323202","preferredDefinition":"A carcinoma originating in the lung.  Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas.  Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas.  Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors. -- 2004: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Carcinoma","conceptCode":"C4878","definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-AFBF-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"94A8083D-5328-774D-E053-F662850A3F57","beginDate":"2019-10-11","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-10-11","modifiedBy":"ONEDATA","dateModified":"2019-10-11","deletedIndicator":"No"},{"value":"Gastric cancer, NOS","valueDescription":"Gastric Carcinoma Not Otherwise Specified","ValueMeaning":{"publicId":"6976257","version":"1","preferredName":"Gastric Carcinoma Not Otherwise Specified","longName":"6976257","preferredDefinition":"A malignant epithelial tumor of the stomach mucosa. The vast majority of gastric carcinomas are adenocarcinomas, arising from the gastric glandular epithelium.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Carcinoma","conceptCode":"C4911","definition":"A malignant epithelial tumor of the stomach mucosa. The vast majority of gastric carcinomas are adenocarcinomas, arising from the gastric glandular epithelium.","evsSource":"RADLEX_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9492724C-BF8E-132C-E053-F662850A32DE","latestVersionIndicator":"Yes","beginDate":"2019-10-10","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-10-10","modifiedBy":"ONEDATA","dateModified":"2019-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9492724C-BFA9-132C-E053-F662850A32DE","beginDate":"2019-10-10","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-10-10","modifiedBy":"ONEDATA","dateModified":"2019-10-10","deletedIndicator":"No"},{"value":"Precursor B-lymphoblastic lymphoma","valueDescription":"B Lymphoblastic Lymphoma","ValueMeaning":{"publicId":"4722715","version":"1","preferredName":"B Lymphoblastic Lymphoma","longName":"4722715","preferredDefinition":"An uncommon type of lymphoma.  It constitutes approximately 10% of cases of lymphoblastic lymphoma.  Approximately 75% of cases reported in a literature review involved patients who were less than 18 years of age.  The most commonly affected sites are the skin, bone, soft tissue, and lymph nodes.  It has a high remission rate with a median survival of approximately 60 months.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Lymphoma","conceptCode":"C8868","definition":"An uncommon type of lymphoma.  It constitutes approximately 10% of cases of lymphoblastic lymphoma.  Approximately 75% of cases reported in a literature review involved patients who were less than 18 years of age.  The most commonly affected sites are the skin, bone, soft tissue, and lymph nodes.  It has a high remission rate with a median survival of approximately 60 months.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C32A-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC38EA51-5BB1-14E6-E053-4EBD850AFF09","beginDate":"2020-08-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-08-06","modifiedBy":"ONEDATA","dateModified":"2020-08-06","deletedIndicator":"No"},{"value":"Precursor T-lymphoblastic lymphoma","valueDescription":"T Lymphoblastic Lymphoma","ValueMeaning":{"publicId":"3251335","version":"1","preferredName":"T Lymphoblastic Lymphoma","longName":"3251335","preferredDefinition":"The most frequent type of lymphoblastic lymphoma.  It comprises approximately 85-90% of cases.  It is more frequently seen in adolescent males.  It frequently presents with a mass lesion in the mediastinum.  Pleural effusions are common.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Lymphoblastic Lymphoma","conceptCode":"C6919","definition":"The most frequent type of lymphoblastic lymphoma.  It comprises approximately 85-90% of cases.  It is more frequently seen in adolescent males.  It frequently presents with a mass lesion in the mediastinum.  Pleural effusions are common.  (WHO, 2001)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9D09-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC38EA51-5B9C-14E6-E053-4EBD850AFF09","beginDate":"2020-08-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-08-06","modifiedBy":"ONEDATA","dateModified":"2020-08-06","deletedIndicator":"No"},{"value":"Thyroid cancer, NOS","valueDescription":"Thyroid Gland Carcinoma Not Otherwise Specified","ValueMeaning":{"publicId":"7346616","version":"1","preferredName":"Thyroid Gland Carcinoma Not Otherwise Specified","longName":"7346616","preferredDefinition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and undifferentiated (anaplastic) carcinoma.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Carcinoma","conceptCode":"C4815","definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A951091B-EB64-7716-E053-4EBD850ABC8E","latestVersionIndicator":"Yes","beginDate":"2020-06-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-30","modifiedBy":"ONEDATA","dateModified":"2020-06-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A951091B-EB7D-7716-E053-4EBD850ABC8E","beginDate":"2020-06-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-30","modifiedBy":"ONEDATA","dateModified":"2020-06-30","deletedIndicator":"No"},{"value":"Renal cell carcinoma, NOS","valueDescription":"Renal Cell Carcinoma Not Otherwise Specified","ValueMeaning":{"publicId":"7346617","version":"1","preferredName":"Renal Cell Carcinoma Not Otherwise Specified","longName":"7346617","preferredDefinition":"The most common type of kidney cancer. It begins in the lining of the renal tubules in the kidney. The renal tubules filter the blood and produce urine.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renal Cell Carcinoma","conceptCode":"C9385","definition":"A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A951091B-EB8A-7716-E053-4EBD850ABC8E","latestVersionIndicator":"Yes","beginDate":"2020-06-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-30","modifiedBy":"ONEDATA","dateModified":"2020-06-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A951091B-EBA3-7716-E053-4EBD850ABC8E","beginDate":"2020-06-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-30","modifiedBy":"ONEDATA","dateModified":"2020-06-30","deletedIndicator":"No"},{"value":"Bone cancer, NOS","valueDescription":"Malignant Bone Neoplasm","ValueMeaning":{"publicId":"5581327","version":"1","preferredName":"Malignant Bone Neoplasm","longName":"5581327","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Bone Neoplasm","conceptCode":"C4016","definition":"A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B68A-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CADA7478-959F-023B-E053-4EBD850AA50B","beginDate":"2021-08-31","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-08-31","modifiedBy":"ONEDATA","dateModified":"2021-08-31","deletedIndicator":"No"},{"value":"Melanoma","valueDescription":"Melanoma","ValueMeaning":{"publicId":"2561514","version":"1","preferredName":"Melanoma","longName":"2561514","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD57-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-05","modifiedBy":"COOPERM","dateModified":"2018-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CADA7478-95AA-023B-E053-4EBD850AA50B","beginDate":"2021-08-31","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-08-31","modifiedBy":"ONEDATA","dateModified":"2021-08-31","deletedIndicator":"No"},{"value":"Testicular nonseminomatous germ cell tumor, NOS","valueDescription":"Malignant Testicular Non-Seminomatous Germ Cell Tumor","ValueMeaning":{"publicId":"4722791","version":"1","preferredName":"Malignant Testicular Non-Seminomatous Germ Cell Tumor","longName":"4722791","preferredDefinition":"A classification of testicular cancers that arise in specialized sex cells called germ cells. Nonseminomas include embryonal carcinoma, teratoma, choriocarcinoma, and yolk sac tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Testicular Non-Seminomatous Germ Cell Tumor","conceptCode":"C5027","definition":"A classification of testicular cancers that arise in specialized sex cells called germ cells. Nonseminomas include embryonal carcinoma, teratoma, choriocarcinoma, and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-247B-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CADA7478-95BE-023B-E053-4EBD850AA50B","beginDate":"2021-08-31","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-08-31","modifiedBy":"ONEDATA","dateModified":"2021-08-31","deletedIndicator":"No"},{"value":"Non-Rhabdomyosarcoma soft tissue sarcoma, NOS","valueDescription":"Soft Tissue Sarcoma","ValueMeaning":{"publicId":"3384698","version":"1","preferredName":"Soft Tissue Sarcoma","longName":"3384698","preferredDefinition":"A malignant mesenchymal neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Soft Tissue Sarcoma","conceptCode":"C9306","definition":"A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9A3DDB0-75C8-1600-E040-BB89AD432CFF","latestVersionIndicator":"Yes","beginDate":"2012-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CADA7478-95D3-023B-E053-4EBD850AA50B","beginDate":"2021-08-31","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-08-31","modifiedBy":"ONEDATA","dateModified":"2021-08-31","deletedIndicator":"No"},{"value":"Miscellaneous neoplasm, NOS","valueDescription":"Miscellaneous Neoplasm","ValueMeaning":{"publicId":"4722607","version":"1","preferredName":"Miscellaneous Neoplasm","longName":"4722607","preferredDefinition":"A benign or malignant neoplasm which is not further characterized.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Miscellaneous Neoplasm","conceptCode":"C102883","definition":"A benign or malignant neoplasm which is not further characterized.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F9CA-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CADA7478-95E8-023B-E053-4EBD850AA50B","beginDate":"2021-08-31","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-08-31","modifiedBy":"ONEDATA","dateModified":"2021-08-31","deletedIndicator":"No"},{"value":"Lymphoma, NOS","valueDescription":"Lymphoma","ValueMeaning":{"publicId":"5581337","version":"1","preferredName":"Lymphoma","longName":"5581337","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B7F3-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CADA7478-95FD-023B-E053-4EBD850AA50B","beginDate":"2021-08-31","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-08-31","modifiedBy":"ONEDATA","dateModified":"2021-08-31","deletedIndicator":"No"},{"value":"Leukemia, NOS","valueDescription":"Leukemia","ValueMeaning":{"publicId":"3179697","version":"1","preferredName":"Leukemia","longName":"3179697","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F258D4-9F60-3E56-E040-BB89AD436715","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CADA7478-9612-023B-E053-4EBD850AA50B","beginDate":"2021-08-31","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-08-31","modifiedBy":"ONEDATA","dateModified":"2021-08-31","deletedIndicator":"No"},{"value":"Colorectal cancer, NOS","valueDescription":"Colorectal Carcinoma","ValueMeaning":{"publicId":"4722734","version":"1","preferredName":"Colorectal Carcinoma","longName":"4722734","preferredDefinition":"A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colorectal Carcinoma","conceptCode":"C2955","definition":"A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1E70-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CADA7478-9627-023B-E053-4EBD850AA50B","beginDate":"2021-08-31","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-08-31","modifiedBy":"ONEDATA","dateModified":"2021-08-31","deletedIndicator":"No"},{"value":"Cervical cancer, NOS","valueDescription":"Cervical Carcinoma","ValueMeaning":{"publicId":"5581330","version":"1","preferredName":"Cervical Carcinoma","longName":"5581330","preferredDefinition":"A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma and undifferentiated carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Carcinoma","conceptCode":"C9039","definition":"A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are squamous cell carcinoma and adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B6F3-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CADA7478-963C-023B-E053-4EBD850AA50B","beginDate":"2021-08-31","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-08-31","modifiedBy":"ONEDATA","dateModified":"2021-08-31","deletedIndicator":"No"},{"value":"Solid Tumor, NOS","valueDescription":null,"ValueMeaning":{"publicId":"5438011","version":"1","preferredName":"Solid Neoplasm","longName":"5438011","preferredDefinition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas. Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma). Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B3C588B-6791-0A60-E050-BB89AD432BC1","latestVersionIndicator":"Yes","beginDate":"2016-08-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F1FF1AE6-AB51-58FF-E053-731AD00A6F1F","beginDate":"2023-01-11","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-11","modifiedBy":"FINCHAMB","dateModified":"2023-01-11","deletedIndicator":"No"},{"value":"Small Cell Lung Cancer","valueDescription":null,"ValueMeaning":{"publicId":"3297699","version":"1","preferredName":"Small Cell Lung Carcinoma","longName":"3297699","preferredDefinition":"A highly aggressive subtype of lung carcinoma characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Small Cell Carcinoma","conceptCode":"C4917","definition":"A highly aggressive carcinoma with neuroendocrine differentiation arising from the lung. It is characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B035F07A-837C-9251-E040-BB89AD4303FC","latestVersionIndicator":"Yes","beginDate":"2011-10-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-26","modifiedBy":"FINCHAMB","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB47EAD9-5801-039B-E053-731AD00A2BEC","beginDate":"2023-05-09","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-09","modifiedBy":"TSESU","dateModified":"2023-05-09","deletedIndicator":"No"},{"value":"Gastrointestinal Cancer","valueDescription":null,"ValueMeaning":{"publicId":"4722726","version":"1","preferredName":"Malignant Digestive System Neoplasm","longName":"4722726","preferredDefinition":"A primary or metastatic malignant neoplasm involving any part of the digestive system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Digestive System Neoplasm","conceptCode":"C4890","definition":"A primary or metastatic malignant neoplasm involving any part of the digestive system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1D9E-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB47EAD9-5802-039B-E053-731AD00A2BEC","beginDate":"2023-05-09","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-09","modifiedBy":"TSESU","dateModified":"2023-05-09","deletedIndicator":"No"},{"value":"Non-Small Cell Lung Cancer","valueDescription":null,"ValueMeaning":{"publicId":"3534668","version":"1","preferredName":"NSCLC","longName":"3534668","preferredDefinition":"A group of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.  Non-small cell lung carcinomas have a poor response to conventional chemotherapy.  --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Non-Small Cell Carcinoma","conceptCode":"C2926","definition":"A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C597D472-1BE4-C3F6-E040-BB89AD434BBD","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-24","modifiedBy":"FINCHAMB","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB6D0D90-D529-1098-E053-731AD00ADAA1","beginDate":"2023-05-11","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-11","modifiedBy":"TSESU","dateModified":"2023-05-11","deletedIndicator":"No"},{"value":"Renal cell carcinoma","valueDescription":null,"ValueMeaning":{"publicId":"3248535","version":"1","preferredName":"Renal Cell Carcinoma","longName":"3248535","preferredDefinition":"Cancer that develops in the lining of the renal tubules, which filter the blood and produce urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renal Cell Carcinoma","conceptCode":"C9385","definition":"A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-BA15-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"FINCHAMB","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB6D0D90-D52A-1098-E053-731AD00ADAA1","beginDate":"2023-05-11","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-11","modifiedBy":"TSESU","dateModified":"2023-05-11","deletedIndicator":"No"},{"value":"Breast Cancer","valueDescription":null,"ValueMeaning":{"publicId":"5581329","version":"1","preferredName":"Breast Carcinoma","longName":"5581329","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B6D0-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"FINCHAMB","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB6D0D90-D52B-1098-E053-731AD00ADAA1","beginDate":"2023-05-11","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-11","modifiedBy":"TSESU","dateModified":"2023-05-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74F8AF0F-EC69-C21E-E040-BB89AD430CC6","latestVersionIndicator":"Yes","beginDate":"2009-10-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-02","modifiedBy":"TSESU","dateModified":"2023-05-11","changeDescription":"6/30/20 added 2 PVs/LD; tmt. 2/8/18 tt added 4 PVs and transferred ownership/BC. 11/5/15 added single PV; tt. 8/31/2021wz: added 8 new PVs and the definitions for t 5 PVs without the definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient's simplified disease","type":"Preferred Question Text","description":"Patient's simplified disease code","url":null,"context":"CTEP"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Primary Tumor Site","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74F8AF0F-ECB1-C21E-E040-BB89AD430CC6","latestVersionIndicator":"Yes","beginDate":"2009-10-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-02","modifiedBy":"TSESU","dateModified":"2023-05-09","changeDescription":"2/8/18 edit to short name to allow ownership transfer from CTEP to ECOG-ACRIN.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}